title: Fasting apoprotein B-48 level and coronary artery disease in a population without frank fasting hypertriglyceridemia.
abstract: The aim of this study was to test the hypothesis that fasting apoprotein B-48 level might be a surrogate marker of postprandial lipemia in evaluating the risk of coronary artery disease (CAD) in a population without frank abnormality in fasting lipid profile. One hundred twenty-three patients tested by coronary angiography were selected on the criteria of absence of treatment with hypolipidemic drugs, obvious hypertriglyceridemia (>2.85 mmol/L), or other conditions that may interfere with lipoprotein metabolism except diabetes. CAD was defined by more than 50% narrowing of vessel lumen, and its severity is determined by the number of arteries involved. Fasting apoprotein B-48 was measured by a competitive enzyme-linked immunosorbent assay method. There was no difference in fasting apoprotein B-48 levels between the groups with and without CAD (0.123+/-0.096 vs 0.136+/-0.125 microg/mL, respectively), whatever the sex or whether with or without diabetes. The apoprotein B-48 level was not related to the presence or the severity of CAD. There was also no correlation between fasting apoprotein B-48 levels and age, sex, body mass index, and usual fasting lipid parameters in both patients with and without angiographically proven CAD. Finally, among the features of metabolic syndrome, apoprotein B-48 was correlated with fasting triglyceride levels (r=0.357, P<.01) only. In conclusion, the present study shows that in the absence of any major fasting abnormality in plasma lipid parameters, fasting apoprotein B-48 level, which has been associated with postprandial hyperlipidemia, does not predict the risk of CAD.
authors.affiliation: Service de Nutrition-Maladies Métaboliques-Endocrinologie, AP-HM, Hôpital Ste Marguerite, Université de la Méditerranée, CHU Marseille, BP 29-13274 Marseille Cedex 09, France. rvalero@mail.ap-hm.fr
authors.forename: René
authors.initials: R
authors.lastname: Valero
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Lorec
authors.forename: Franck
authors.initials: F
authors.lastname: Paganelli
authors.forename: Sophie
authors.initials: S
authors.lastname: Beliard
authors.forename: Catherine
authors.initials: C
authors.lastname: Atlan
authors.forename: Denis
authors.initials: D
authors.lastname: Lairon
authors.forename: Bernard
authors.initials: B
authors.lastname: Vialettes
authors.forename: Henri
authors.initials: H
authors.lastname: Portugal
mesh_terms: D000368:Aged; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D002784:Cholesterol / Q000097:blood; D003324:Coronary Artery Disease / Q000453:epidemiology* / Q000378:metabolism*; D005215:Fasting; D005260:Female; D006801:Humans; D015228:Hypertriglyceridemia; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D015415:Biomarkers; D014280:Triglycerides; D002784:Cholesterol